<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267396</url>
  </required_header>
  <id_info>
    <org_study_id>06-VIN-103</org_study_id>
    <nct_id>NCT01267396</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fasting Conditions in Healthy Human Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare and evaluate the single-dose oral bioavailability
      of the test formulation of Sertraline Hydrochloride 100 mg tablets (Dr. Reddy's Laboratories
      Limited) with the reference formulation ZOLOFT® 100 mg Tablet (Pfizer)under fasting
      conditions in healthy adult human subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose,
      Crossover, Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's
      Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer,
      USA)Under Fasting Conditions in Healthy Human Adult Subjects. 32 healthy, adult, human male
      subjects were enrolled in the study and all the subjected completed all the periods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sertraline Hydrochloride tablets 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoloft 100 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoloft 100 mg Tablets of Pfizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Sertraline Hydrochloride Tablets 100 mg</description>
    <arm_group_label>Sertraline Hydrochloride tablets 100 mg</arm_group_label>
    <arm_group_label>Zoloft 100 mg Tablets</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy human subjects ages 18 and 45 years (including both).

          2. Subjects weight within the normal range according to normal values for the body mass
             index (18.5 to 24.9 kg/m2) with minimum of 50 kg weight.

          3. Subjects with normal health as determined by personal medical history, clinical
             examination and laboratory examinations within the clinically acceptable normal rane.

          4. Subjects having normal 12-lead electrocardiogram (ECG)

          5. Subjects having normal chest X-Ray (P/A view)

          6. Subjects having negative urine screen for drugs of abuse(including amphetamines,
             barbiturates, benzodiazepines, marijuana, cocaine, and morphine).

          7. Subjects having negative alcohol breath test

          8. Subjects willing to adhere to the protocol requirements and to provide written
             informed consent.

        For Female Subjects:

          1. Female of child bearing potential practicing an acceptable method of birth control for
             the duration of the study as judged by the investigator(s), such as condoms, foams,
             jellies,diaphragm, intrauterine devise(IUD) or abstinence, or

          2. Postmenopausal for at least 1 year or

          3. Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
             has been performed on the subject.

        Exclusion Criteria:

          1. Hypersensitivity to sertraline hydrochloride or related class of drugs.

          2. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological neurological or psychiatric
             disease or disorder.

          3. Any treatment which could bring about induction or inhibition of hepatic microsomal
             enzyme system within 1 month of the study starting.

          4. History or presence of significant alcoholism or drug abuse in the past one year.

          5. History or presence of significant smoking (more than 10 cigarettes day) or
             consumption of tobacco products.

          6. History or presence of significant asthma, urticaria or other allergic reactions.

          7. History or presence of significant gastric and/or duodenal ulceration.

          8. History or presence of significant thyroid disease, adrenal dysfunction, organic
             intracranial lesion such as pituitary tumor.

          9. History or presence of cancer

         10. History or presence of significant easy bruising or bleeding

         11. History or presence of significant recent trauma

         12. Subjects who have been on an abnormal diet(for whatever reason) during the four weeks
             preceding the study.

         13. Difficulty with donating blood

         14. Difficulty in swallowing solids like tablets or capsules

         15. Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg

         16. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.

         17. Pulse rate less than 50/minute or more than 100/minute

         18. Oral temperature less than 95ºF or more than 98.6ºF.

         19. Respiratory rate less than 12/minute or more than 20/minute

         20. Use of any prescribed medication during last two weeks or OTC medical products during
             the last week prior to initiation or study

         21. Major illness during 3 months before screening

         22. Participation in a drug research study within past 3 months

         23. Donation of blood in the past 3 months before screening.

        For Female Subjects:

        Female subjects who are pregnant or who are able (women with child bearing potential) to
        become pregnant during the study were not allowed to participate.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damesh Domadia, MBBS, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veeda Clinical Research (P) Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veeda Clinical Research (P) Ltd</name>
      <address>
        <city>Ambawadi</city>
        <state>Ahmedabad</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2010</study_first_submitted>
  <study_first_submitted_qc>December 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2010</study_first_posted>
  <last_update_submitted>January 10, 2012</last_update_submitted>
  <last_update_submitted_qc>January 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <name_title>Sr. Director- Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Sertraline</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

